EAMC reduces number of first-dose vaccine appointments
OPELIKA, Ala. (WTVM) - Thousands of people have received their first dose of Pfizer’s COVID-19 vaccine in the past three weeks at the East Alabama Medical Center’s (EAMC) community vaccine clinic.
Now, officials say it is time for many to receive their second shot.
Sonya Mocks received her first dose at the community vaccine clinic last week.
“There were people there, but it worked like clockwork,” she said. “It was a great experience, considering I was there for a vaccination.”
She is now scheduled to get that second dose in a few weeks.
“I’m not as apprehensive about it as I was in the beginning,” Mocks said.
According to EAMC, to accommodate the number of people like Mocks who need their second COVID-19 shot, about 800 of the roughly 1,200 doses EAMC administers daily will go to those receiving a second dose.
“I think about two-thirds will be second doses,” said John Atkinson, EAMC’s PR and marketing director. “So, that does leave about a one-third of shots available for people trying to get their first dose still.”
According to hospital leaders, on March 15, the pattern will switch.
“It’ll be just the other way around,” Atkinson said. “[In three weeks] we’ll have 800 new first doses to be available and only 400 second doses.”
When it comes to long-term plans, officials with EAMC said they plan to keep the clinic open until at least the end of April.
“We’ll just have to evaluate it each month and see how it goes and see if there’s more vaccine in the community by then,” Atkinson said.
Having the clinic open longer is something Mocks said is a good thing.
“As we see more and more people getting vaccinated, then it gives people the courage to say okay, ‘I’m going to go ahead and do it,’” Mocks said. “And when the process is as simple as what I went through, then you don’t mind.”
INDIANAPOLIS, Jan. 11, 2021 /PRNewswire/ -- Vaccines for the COVID-19 virus have begun to roll out across the United States, and eCoronaPass is helping lead the charge with its new software platform that effectively manages vaccination scheduling, symptom tracking, and data reporting that is needed by government entities, health systems, and private employers.
The rollout of the coronavirus vaccine has already experienced some struggles with states scrambling to distribute the available COVID-19 vaccines. Softbir has created eCoronaPass to redesign how these vaccines should be properly managed and distributed. Softbir believes its platform is the answer and solution to all these complicated issues.
"Our eCoronaPass software has been an effective platform for healthcare providers offering COVID testing services since the beginning of the pandemic. We knew that optimizing our software to be able to incorporate effective modules for the vaccination rollout was necessary for successful implementation. It is more critical than ever to rapidly deploy these vaccines with ease of use to healthcare providers and suppliers."
Safe, Reliable, Fast & Easy-to-Use Software
The platform is built and supported through Amazon Web Services (AWS), making it the most reliable and easily accessible cloud platform for any client to use.
eCoronaPass is also compliant with HIPAA, HITECH, and NIST standards, and follows all FDA/CDC regulations, allowing for a safe and secure portal for patients and providers.
Proactive Deployment Monitoring of Vaccines
eCoronaPass will save lives by effectively managing and proactively monitoring the implementation of the vaccines. Deployment of vaccines will be faster, more agile, and easier than ever, allowing for scheduling of COVID-19 testing services and vaccinations.
Patients can take control of their health by scheduling appointments with approved sites that fit their availability and needs. The locator module allows for patients to find areas nearest to them to get vaccinated as quickly as possible.
Effectiveness and Symptom Tracking
With its comprehensive COVID-19 test tracking and automated vaccine reporting, eCoronaPass will give patients peace-of-mind.
They will be able to self-monitor adverse vaccine reactions with data transferred automatically to the CDC directly via the Vaccine Adverse Event Reporting System (VAERS).
The effectiveness and symptoms tracking feature between the multiple available COVID-19 vaccines provide data for informed decision-making, ultimately improving population health.
Real-Time Adverse Effects Data
eCoronaPass includes administrative prioritization selection technology, with features including effective patient health-risk stratification and predictive care modules. One can pinpoint and select which populations will be segmented into different phases of vaccination programs. The platform is also powered to expand any contraindications as they are determined.
The platform displays a dashboard of real-time data regarding a population's health status, enabling a proactive reaction to the adverse effects of all available COVID-19 vaccines.
If you would like to learn more click HERE for a short explanation video.
Jim Ray Rodriguez